Answers are grounded in this paper and cite their sources.
Vitreoretinal involvement of lymphoma can be controlled effectively and without serious adverse reactions by intravitreal MTX injections. The treatment protocol described herein has resulted in no intraocular recurrence so far and has had bearable side effects. The accumulating clinical results bring us to propose the consideration of this protocol as a good first-line treatment option for intraocular lymphoma.
No takes yet. Share an insight, caveat, or question.
Frenkel et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: